Leerink Partnrs Issues Pessimistic Outlook for BPMC Earnings

Blueprint Medicines Co. (NASDAQ:BPMC) – Research analysts at Leerink Partnrs decreased their FY2025 earnings estimates for Blueprint Medicines in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will post earnings of ($1.24) per share for the year, down from their prior forecast of ($0.99). The consensus estimate for Blueprint Medicines’ current full-year earnings is ($3.63) per share.

A number of other equities research analysts also recently commented on the company. UBS Group initiated coverage on Blueprint Medicines in a report on Thursday, October 24th. They set a “neutral” rating and a $88.00 target price for the company. Wells Fargo & Company decreased their price objective on shares of Blueprint Medicines from $153.00 to $151.00 and set an “overweight” rating for the company in a research note on Thursday, October 31st. JPMorgan Chase & Co. increased their price objective on shares of Blueprint Medicines from $126.00 to $129.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. StockNews.com upgraded shares of Blueprint Medicines from a “sell” rating to a “hold” rating in a research report on Friday, November 8th. Finally, JMP Securities reiterated a “market outperform” rating and set a $125.00 price objective on shares of Blueprint Medicines in a research note on Wednesday, January 15th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $123.72.

Blueprint Medicines Stock Performance

Shares of BPMC opened at $104.00 on Monday. The stock has a 50-day moving average of $99.41 and a two-hundred day moving average of $94.78. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.27 and a current ratio of 3.32. The stock has a market cap of $6.61 billion, a P/E ratio of -49.29 and a beta of 0.62. Blueprint Medicines has a one year low of $72.24 and a one year high of $121.90.

Institutional Trading of Blueprint Medicines

Institutional investors have recently made changes to their positions in the company. CWM LLC grew its holdings in shares of Blueprint Medicines by 69.2% during the 3rd quarter. CWM LLC now owns 1,870 shares of the biotechnology company’s stock worth $173,000 after purchasing an additional 765 shares during the period. Essex Investment Management Co. LLC acquired a new position in Blueprint Medicines in the third quarter valued at about $3,280,000. Creative Planning boosted its stake in Blueprint Medicines by 6.8% during the third quarter. Creative Planning now owns 13,194 shares of the biotechnology company’s stock worth $1,220,000 after buying an additional 843 shares during the period. NBC Securities Inc. increased its position in shares of Blueprint Medicines by 748.9% during the third quarter. NBC Securities Inc. now owns 2,725 shares of the biotechnology company’s stock valued at $252,000 after acquiring an additional 2,404 shares during the last quarter. Finally, Teamwork Financial Advisors LLC purchased a new stake in shares of Blueprint Medicines in the 3rd quarter valued at approximately $250,000.

Insider Transactions at Blueprint Medicines

In other news, CEO Kate Haviland sold 1,446 shares of Blueprint Medicines stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $110.24, for a total transaction of $159,407.04. Following the transaction, the chief executive officer now owns 149,378 shares in the company, valued at $16,467,430.72. The trade was a 0.96 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Ariel Hurley sold 1,819 shares of the company’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $93.26, for a total transaction of $169,639.94. Following the completion of the sale, the insider now directly owns 14,967 shares of the company’s stock, valued at $1,395,822.42. This represents a 10.84 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 49,851 shares of company stock valued at $4,984,696. Corporate insiders own 4.21% of the company’s stock.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.